These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19004630)

  • 1. Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).
    Vaccaro W; Huynh T; Lloyd J; Atwal K; Finlay HJ; Levesque P; Conder ML; Jenkins-West T; Shi H; Sun L
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6381-5. PubMed ID: 19004630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
    Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.
    Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Finlay W; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Arbuckle W; Anderson M; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Jones P; Uitdehaag JC; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6237-41. PubMed ID: 20843687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
    Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
    Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
    Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
    J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
    Petrocchi A; Jones P; Rowley M; Fiore F; Summa V
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4245-9. PubMed ID: 19523819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
    Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
    Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
    Beshore DC; Liverton NJ; McIntyre CJ; Claiborne CF; Libby B; Culberson JC; Salata JJ; Regan CP; Lynch JJ; Kiss L; Spencer RH; Kane SA; White RB; Yeh S; Hartman GD; Dinsmore CJ
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2493-6. PubMed ID: 20304642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary SAR studies on non-apamin-displacing 4-(aminomethylaryl)pyrrazolopyrimidine K(Ca) channel blockers.
    Gentles RG; Hu S; Huang Y; Grant-Young K; Poss MA; Andres C; Fiedler T; Knox R; Lodge N; Weaver CD; Harden DG
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5694-7. PubMed ID: 18824351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
    Finlay HJ; Jiang J; Caringal Y; Kover A; Conder ML; Xing D; Levesque P; Harper T; Hsueh MM; Atwal K; Blanar M; Wexler R; Lloyd J
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1743-7. PubMed ID: 23414837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
    Carter DS; Alam M; Cai H; Dillon MP; Ford AP; Gever JR; Jahangir A; Lin C; Moore AG; Wagner PJ; Zhai Y
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1628-31. PubMed ID: 19231180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrano-[2,3b]-pyridines as potassium channel antagonists.
    Finlay HJ; Lloyd J; Nyman M; Conder ML; West T; Levesque P; Atwal K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2714-8. PubMed ID: 18374568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
    Johnson JA; Xu N; Jeon Y; Finlay HJ; Kover A; Conder ML; Sun H; Li D; Levesque P; Hsueh MM; Harper TW; Wexler RR; Lloyd J
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3018-22. PubMed ID: 24881565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
    Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
    Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
    Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
    Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
    Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.
    Holsworth DD; Jalaie M; Belliotti T; Cai C; Collard W; Ferreira S; Powell NA; Stier M; Zhang E; McConnell P; Mochalkin I; Ryan MJ; Bryant J; Li T; Kasani A; Subedi R; Maiti SN; Edmunds JJ
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3575-80. PubMed ID: 17482464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.
    Ishida H; Isami S; Matsumura T; Umehara H; Yamashita Y; Kajita J; Fuse E; Kiyoi H; Naoe T; Akinaga S; Shiotsu Y; Arai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5472-7. PubMed ID: 18835166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.